Update shared on08 Sep 2025
Fair value Increased 6.32%Analysts have raised Avadel Pharmaceuticals' fair value target from $19.00 to $20.20, citing improved commercial execution for Lumryz and pipeline expansion opportunities, though some caution over competition and valuation is noted.
Analyst Commentary
- Bullish analysts highlight commercial execution gains, with improved persistency trends and increasing reimbursed Lumryz patient counts driving revenue upside.
- Further growth potential is seen through expansion into idiopathic hypersomnia and the development of a low-salt oxybate formulation.
- Bullish analysts view these pipeline efforts as possible upside drivers to the current valuation.
- Some bearish analysts believe current market prices already account for recent commercial outperformance, reducing near-term upside.
- Bearish analysts cite potential competition risks from Xyrem generics and future orexin-based entrants, which could pressure Lumryz's long-term growth prospects.
What's in the News
- Avadel will present new data supporting LUMRYZ for narcolepsy at World Sleep 2025, with interim results from the REFRESH real-world study showing improvements in sleepiness, narcolepsy symptoms, and quality of life for both switch and naive patients.
- The FDA has approved LUMRYZ as a once-at-bedtime treatment for cataplexy or EDS in adults and pediatric patients aged seven and older; the product is supported by robust clinical trial outcomes and recently received orphan drug designation for idiopathic hypersomnia.
- Avadel raised full-year 2025 revenue guidance to $265–$275 million and expects Q3 net product revenue of $71–$75 million.
- Activist investor ASL Strategic Value Fund is urging shareholders to vote against Avadel’s board nominees and demanding an impartial election monitor, citing past voting irregularities and advocating for monetization of LUMRYZ’s value, especially with its new indication potential in idiopathic hypersomnia.
- The U.S. Court of Appeals upheld the FDA’s approval of LUMRYZ following a legal challenge by Jazz Pharmaceuticals; Avadel was also added to the S&P TMI Index.
Valuation Changes
Summary of Valuation Changes for Avadel Pharmaceuticals
- The Consensus Analyst Price Target has risen from $19.00 to $20.20.
- The Future P/E for Avadel Pharmaceuticals has significantly risen from 17.16x to 20.63x.
- The Net Profit Margin for Avadel Pharmaceuticals has significantly fallen from 30.13% to 26.65%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.